PARP inhibitors

7 · 20 / page

Ask MedXY AI

Latest news

Tag

newsHigh-grade serous carcinomahomologous recombination deficiency

Harnessing HRD Testing and MYC Amplification to Optimize PARP Inhibitor Use in BRCA Wild-Type High-Grade Serous Ovarian Carcinoma

By MedXY|Jul 15, 2026

This article reviews real-world data supporting homologous recombination deficiency (HRD) testing in BRCA1/2 wild-type high-grade serous carcinoma and examines MYC amplification as a promising surrogate biomarker to guide PARP inhibitor the

Long-Term Outcomes and Durability of Exceptional Responses to PARP Inhibitors in Recurrent Platinum-Sensitive Ovarian Cancer

news

PARP inhibitors

Latest news

Harnessing HRD Testing and MYC Amplification to Optimize PARP Inhibitor Use in BRCA Wild-Type High-Grade Serous Ovarian Carcinoma

Long-Term Outcomes and Durability of Exceptional Responses to PARP Inhibitors in Recurrent Platinum-Sensitive Ovarian Cancer

Homologous Recombination Repair Gene Alterations Are Uncommon and Not Prognostic in Molecularly Classified Endometrial Cancer

Synergistic Potential and Hematologic Hurdles: Sapacitabine and Olaparib in BRCA1/2-Mutated Metastatic Breast Cancer

Comprehensive Overview of the AMPLITUDE Trial Results on Niraparib and AAP in HRR-Deficient Prostate Cancer

Underutilization of PARP Inhibitors in Metastatic Prostate Cancer With BRCA1/2 Alterations: Insights from a US Real-World Cohort

PARP inhibitors shine: How the TALAPRO-2 trial is changing the landscape of prostate cancer with precision medicine